182 related articles for article (PubMed ID: 36122756)
1. Immunomodulatory role of Nanocurcumin in COVID-19 patients with dropped natural killer cells frequency and function.
Abbaspour-Aghdam S; Hazrati A; Abdolmohammadi-Vahid S; Tahmasebi S; Mohseni J; Valizadeh H; Nadiri M; Mikaeili H; Sadeghi A; Yousefi M; Roshangar L; Nikzad B; Jadidi-Niaragh F; Kafil HS; Malekpour K; Ahmadi M
Eur J Pharmacol; 2022 Oct; 933():175267. PubMed ID: 36122756
[TBL] [Abstract][Full Text] [Related]
2. Nanocurcumin improves Treg cell responses in patients with mild and severe SARS-CoV2.
Tahmasebi S; Saeed BQ; Temirgalieva E; Yumashev AV; El-Esawi MA; Navashenaq JG; Valizadeh H; Sadeghi A; Aslani S; Yousefi M; Jadidi-Niaragh F; Adigozalou J; Ahmadi M; Roshangar L
Life Sci; 2021 Jul; 276():119437. PubMed ID: 33789145
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory potential of nanocurcumin-based formulation.
Trivedi MK; Mondal SC; Gangwar M; Jana S
Inflammopharmacology; 2017 Dec; 25(6):609-619. PubMed ID: 28921388
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory effects of nanocurcumin on Th17 cell responses in mild and severe COVID-19 patients.
Tahmasebi S; El-Esawi MA; Mahmoud ZH; Timoshin A; Valizadeh H; Roshangar L; Varshoch M; Vaez A; Aslani S; Navashenaq JG; Aghebati-Maleki L; Ahmadi M
J Cell Physiol; 2021 Jul; 236(7):5325-5338. PubMed ID: 33372280
[TBL] [Abstract][Full Text] [Related]
5. The effects of nanocurcumin supplementation on inflammation in hemodialysis patients: A randomized controlled trial.
Vafadar-Afshar G; Rasmi Y; Yaghmaei P; Khadem-Ansari MH; Makhdoomi K; Rasouli J
Hemodial Int; 2021 Apr; 25(2):232-239. PubMed ID: 33559343
[TBL] [Abstract][Full Text] [Related]
6. A comprehensive evaluation of the immune system response and type-I Interferon signaling pathway in hospitalized COVID-19 patients.
Soltani-Zangbar MS; Parhizkar F; Ghaedi E; Tarbiat A; Motavalli R; Alizadegan A; Aghebati-Maleki L; Rostamzadeh D; Yousefzadeh Y; Jadideslam G; Farid SS; Roshangar L; Mahmoodpoor A; Heris JA; Miahipour A; Yousefi M
Cell Commun Signal; 2022 Jul; 20(1):106. PubMed ID: 35842705
[TBL] [Abstract][Full Text] [Related]
7. The effects of nanocurcumin on Treg cell responses and treatment of ankylosing spondylitis patients: A randomized, double-blind, placebo-controlled clinical trial.
Ahmadi M; Hajialilo M; Dolati S; Eghbal-Fard S; Heydarlou H; Ghaebi M; Ghassembaglou A; Aghebati-Maleki L; Samadi Kafil H; Kamrani A; Rahnama B; Rikhtegar R; Yousefi M
J Cell Biochem; 2020 Jan; 121(1):103-110. PubMed ID: 31074089
[TBL] [Abstract][Full Text] [Related]
8. Severe COVID-19 patients display hyper-activated NK cells and NK cell-platelet aggregates.
Malengier-Devlies B; Filtjens J; Ahmadzadeh K; Boeckx B; Vandenhaute J; De Visscher A; Bernaerts E; Mitera T; Jacobs C; Vanderbeke L; Van Mol P; Van Herck Y; Hermans G; Meersseman P; Wilmer A; Gouwy M; Garg AD; Humblet-Baron S; De Smet F; Martinod K; Wauters E; Proost P; Wouters C; Leclercq G; Lambrechts D; Wauters J; Matthys P
Front Immunol; 2022; 13():861251. PubMed ID: 36275702
[TBL] [Abstract][Full Text] [Related]
9. Nanocurcumin modulates Th17 cell responses in moderate and severe COPD patients.
Mardi A; Abdolmohammadi-Vahid S; Sadeghi SA; Jafarzadeh S; Abbaspour-Aghdam S; Hazrati A; Mikaeili H; Valizadeh H; Sadeghi A; Ahmadi M; Nadiri M
Heliyon; 2024 May; 10(9):e30025. PubMed ID: 38737273
[TBL] [Abstract][Full Text] [Related]
10. Nanocurcumin is a potential novel therapy for multiple sclerosis by influencing inflammatory mediators.
Dolati S; Ahmadi M; Aghebti-Maleki L; Nikmaram A; Marofi F; Rikhtegar R; Ayromlou H; Yousefi M
Pharmacol Rep; 2018 Dec; 70(6):1158-1167. PubMed ID: 30340096
[TBL] [Abstract][Full Text] [Related]
11. Immune modulation as a consequence of SARS-CoV-2 infection.
Gelmez MY; Oktelik FB; Tahrali I; Yilmaz V; Kucuksezer UC; Akdeniz N; Cetin EA; Kose M; Cinar C; Oguz FS; Besisik S; Koksalan K; Ozdemir O; Senkal N; Gul A; Tuzun E; Deniz G
Front Immunol; 2022; 13():954391. PubMed ID: 36110850
[TBL] [Abstract][Full Text] [Related]
12. Nanocurcumin: A novel strategy in treating ankylosing spondylitis by modulating Th17 cells frequency and function.
Hajialilo M; Dolati S; Abdolmohammadi-Vahid S; Ahmadi M; Kamrani A; Eghbal-Fard S; Ghassembaglou A; Valizadeh A; Shenas MHM; Aghebati-Maleki L; Kafil HS; Mehdizadeh A; Yousefi M
J Cell Biochem; 2019 Jul; 120(7):12027-12038. PubMed ID: 30805973
[TBL] [Abstract][Full Text] [Related]
13. Il-21 enhances NK cell activation and cytolytic activity and induces Th17 cell differentiation in inflammatory bowel disease.
Liu Z; Yang L; Cui Y; Wang X; Guo C; Huang Z; Kan Q; Liu Z; Liu Y
Inflamm Bowel Dis; 2009 Aug; 15(8):1133-44. PubMed ID: 19322899
[TBL] [Abstract][Full Text] [Related]
14. Chronic nanocurcumin treatment ameliorates pain-related behavior, improves spatial memory, and reduces hippocampal levels of IL-1β and TNFα in the chronic constriction injury model of neuropathic pain.
Saffarpour S; Janzadeh A; Rahimi B; Ramezani F; Nasirinezhad F
Psychopharmacology (Berl); 2021 Mar; 238(3):877-886. PubMed ID: 33404738
[TBL] [Abstract][Full Text] [Related]
15. Changes in Th17 cells function after nanocurcumin use to treat multiple sclerosis.
Dolati S; Ahmadi M; Rikhtegar R; Babaloo Z; Ayromlou H; Aghebati-Maleki L; Nouri M; Yousefi M
Int Immunopharmacol; 2018 Aug; 61():74-81. PubMed ID: 29852475
[TBL] [Abstract][Full Text] [Related]
16. A novel role for interleukin-18 in human natural killer cell death: high serum levels and low natural killer cell numbers in patients with systemic autoimmune diseases.
Shibatomi K; Ida H; Yamasaki S; Nakashima T; Origuchi T; Kawakami A; Migita K; Kawabe Y; Tsujihata M; Anderson P; Eguchi K
Arthritis Rheum; 2001 Apr; 44(4):884-92. PubMed ID: 11315928
[TBL] [Abstract][Full Text] [Related]
17. Interferon-alpha activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor-alpha secretion by immature human natural killer cells.
Jewett A; Bonavida B
J Clin Immunol; 1995 Jan; 15(1):35-44. PubMed ID: 7759599
[TBL] [Abstract][Full Text] [Related]
18. Nanocurcumin formulation: a possible therapeutic agent for post COVID inflammatory syndrome.
Kushwaha AD; Mishra KP; Singh M; Ganju L; Saraswat D
Immunopharmacol Immunotoxicol; 2022 Apr; 44(2):141-146. PubMed ID: 35130792
[TBL] [Abstract][Full Text] [Related]
19. Effects of nanocurcumin supplementation on T-helper 17 cells inflammatory response in patients with Behcet's disease: a randomized controlled trial.
Farzaneh R; Khabbazi A; Soltani-Zangbar MS; Abbasian S; Malek Mahdavi A; Motavalli R; Yousefi M
Immunopharmacol Immunotoxicol; 2022 Apr; 44(2):206-215. PubMed ID: 35021944
[TBL] [Abstract][Full Text] [Related]
20. Immunoregulatory effects of nanocurcumin in inflammatory milieu: Focus on COVID-19.
Arab FL; Hoseinzadeh A; Mohammadi FS; Rajabian A; Faridzadeh A; Mahmoudi M
Biomed Pharmacother; 2024 Feb; 171():116131. PubMed ID: 38198954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
